Novo Nordisk reports positive semaglutide trial results in young children
The company says the study met its goals in a pediatric population well below the ages covered by current semaglutide labelling.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 8 03:00 ETSource: seekingalpha.com
The wire
- 01Novo Nordisk announced positive results from a semaglutide trial conducted in young children, the company said.
- 02Pediatric data would support a label expansion into an age group clinicians currently treat off-label or not at all with incretins.
- 03Endpoint details, sample size, dosing and safety findings were not disclosed in the announcement; regulatory filings and full data are still to come.
From the source
Read at seekingalpha.comNovo Nordisk reports positive semaglutide trial results in young children (NVO:NYSE)
